Related Experiment Video
Updated: May 29, 2026

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice
Published on: August 2, 2018
Combined deficiency of alpha and epsilon sarcoglycan disrupts the cardiac dystrophin complex
Alessio Lancioni1, Ida Luisa Rotundo, Yvonne Monique Kobayashi
1Telethon Institute of Genetics and Medicine, Via Pietro Castellino 111, Napoli 80131, Italy.
Insights
Epsilon-sarcoglycan (ε-SG) may prevent heart disease in patients with alpha-sarcoglycan (α-SG) deficiency. Mice lacking both α-SG and ε-SG developed severe cardiomyopathy, suggesting ε-SG
Area of Science:
- Muscle biology
- Genetics
- Cardiology
Background:
- Mutations in sarcoglycan (SG) genes cause skeletal muscle pathology.
- Cardiomyopathy is a rare complication in patients with α-SG gene mutations.
- Epsilon-sarcoglycan (ε-SG) is hypothesized to compensate for α-SG deficiency in the heart.
Purpose of the Study:
- To investigate the function of ε-SG in striated muscle.
- To determine if ε-SG compensates for α-SG deficiency in the heart.
- To understand the role of ε-SG in preventing cardiomyopathy.
Main Methods:
- Generated Sgce-null mice (lacking ε-SG).
- Generated Sgca-;Sgce-null mice (lacking both α-SG and ε-SG).
- Phenotypic analysis of generated mouse models.
Main Results:
- Sgce-null mice exhibited a wild-type phenotype without muscular dystrophy or heart disease.
- Sgca-;Sgce-null mice developed progressive muscular dystrophy and severe cardiomyopathy.
- Sgca-;Sgce-null mice showed a complete loss of residual SGs and reduced dystrophin and dystroglycan.
Conclusions:
- Epsilon-sarcoglycan (ε-SG) plays a crucial role in preventing cardiomyopathy associated with α-SG deficiency.
- ε-SG is important for maintaining cardiac function in the context of α-SG loss.
- This study highlights ε-SG as a potential therapeutic target for certain muscular dystrophies.
Abstract:
Cardiomyopathy is a puzzling complication in addition to skeletal muscle pathology for patients with mutations in β-, γ- or δ-sarcoglycan (SG) genes. Patients with mutations in α-SG rarely have associated cardiomyopathy, or their cardiac pathology is very mild. We hypothesize that a fifth SG, ε-SG, may compensate for α-SG deficiency in the heart. To investigate the function of ε-SG in striated muscle, we generated an Sgce-null mouse and a Sgca-;Sgce-null mouse, which lacks both α- and ε-SGs. While Sgce-null mice showed a wild-type phenotype, with no signs of muscular dystrophy or heart disease, the Sgca-;Sgce-null mouse developed a progressive muscular dystrophy and a more anticipated and severe cardiomyopathy. It shows a complete loss of residual SGs and a strong reduction in both dystrophin and dystroglycan. Our data indicate that ε-SG is important in preventing cardiomyopathy in α-SG deficiency.
More Related Videos
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Desmosomes
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy
Satellite Stem Cells and Muscular Dystrophy

